Cabozantinib after immunotherapy in advanced kidney cancer
This recent retrospective study included 84 patients with metastatic renal [...]
Activity of cabozantinib after immunotherapy in advance kidney cancer
A retrospective study published in the European Journal of Cancer [...]
Positive results from trial of cabozantinib plus nivolumab combination in untreated metastatic kidney cancer
Results from the pivotal phase 3 CheckMate-9ER clinical trial evaluating [...]
Cabozantinib in combination with immunotherapy for advanced kidney cancer
In this video interview, Dr Monty Pal from the City [...]
Tivozanib has a better safety profile than other TKIs for the treatment of kidney cancer
A recent literature review and network meta-analysis of phase 2/3 [...]
IKCS 2019: Biomarkers in kidney cancer
In this interview taken from the International Kidney Cancer Symposium [...]
Deciding on the ideal first-line treatment for rare and advanced kidney cancer
Currently, doctors are unsure which is the best first-line treatment [...]
PD-L1 expression and clinical outcomes with targeted therapy
A recent study published in Clinical Cancer Research analysed tumour [...]
Phase Ib cabozantinib plus atezolizumab combination study now open to kidney cancer patients in the UK
Based on promising efficacy findings, the COSMIC-021 clinical trial has [...]
Telaglenastat/cabozantinib combination shows early activity in metastatic kidney cancer
Telaglenastat is an oral glutaminase inhibitor and this is the [...]
